GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cresco Labs Inc (XCNQ:CL) » Definitions » Capex-to-Revenue

Cresco Labs (XCNQ:CL) Capex-to-Revenue : 0.03 (As of Dec. 2023)


View and export this data going back to 1991. Start your Free Trial

What is Cresco Labs Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Cresco Labs's Capital Expenditure for the three months ended in Dec. 2023 was C$-6.95 Mil. Its Revenue for the three months ended in Dec. 2023 was C$252.54 Mil.

Hence, Cresco Labs's Capex-to-Revenue for the three months ended in Dec. 2023 was 0.03.


Cresco Labs Capex-to-Revenue Historical Data

The historical data trend for Cresco Labs's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cresco Labs Capex-to-Revenue Chart

Cresco Labs Annual Data
Trend Jan14 Jan15 Jan16 Jan17 Jan18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.75 0.19 0.12 0.10 0.08

Cresco Labs Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.11 0.09 0.07 0.03

Competitive Comparison of Cresco Labs's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Cresco Labs's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cresco Labs's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cresco Labs's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cresco Labs's Capex-to-Revenue falls into.



Cresco Labs Capex-to-Revenue Calculation

Cresco Labs's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-77.656) / 1034.219
=0.08

Cresco Labs's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-6.952) / 252.539
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cresco Labs  (XCNQ:CL) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Cresco Labs Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cresco Labs's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Cresco Labs (XCNQ:CL) Business Description

Traded in Other Exchanges
Address
400 W. Erie Street, Suite 110, Chicago, IL, USA, 60654
Cresco Labs Inc is a vertically-integrated multi-state cannabis operator in the United States licensed to cultivate, manufacture and sell retail and medical cannabis products through Sunnyside, Cresco Labs' national dispensary brand and third-party retail stores. The Company operates in one segment, the cultivation, manufacturing, distribution and sale of cannabis.